# A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies

> **NCT07135466** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sheba Medical Center** · enrollment: 50 (estimated)

## Conditions studied

- B Cell Malignancies

## Interventions

- **OTHER:** CD22 CAR-T cells

## Key facts

- **NCT ID:** NCT07135466
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2027-04-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07135466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07135466, "A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07135466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*